The Centre will bring activities in patient and public involvement, engagement and participation and research dissemination under one roof.
News
AZ licences Movantik rights to RedHill
AstraZeneca has completed its deal to sublicense certain rights to Movantik to RedHill Biopharma
Positive early data from siltuximab COVID-19 trial
One-third (33%) of patients experienced a clinical improvement with a reduced need for oxygen support
NICE publishes second set of rapid COVID-19 guidelines
The guidelines advise clinicians on modifying care to reduce patients’ exposure to COVID-19 and how to balance the risks and benefits of treatment during the pandemic
EU research-based industry unveils COVID-19 commitments
As of this morning – Wednesday April 1 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 25,150, with 1,789 deaths.
Ethris, Neurimmune work on inhalable COVID-19 therapy
Ethris GmbH and Neurimmune AG are working together on developing an inhalable treatment for COVID-19
Novel micro-RNA therapeutic hits early targets in ischemic heart diseases
Earlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Eli Lilly, Sitryx announce autoimmune alliance
Eli Lilly recently announced plans to postpone most new COVID-19-unrelated study starts.
2020 Marketer of the Year competition opens its doors for entry
The long-standing competition is now open for entry to pharma marketers in a variety of roles and experience levels.
COVID-19: J&J announces vaccine candidate, Synairgen commences dosing
Sense Biodetection has also pitched in, announcing an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for the novel virus.
FDA approves Imfinzi for extensive-stage SCLC
The approval was based on the Phase III CASPIAN trial, in which the risk of death was reduced by 27%.
Nubeqa authorised in Europe for certain prostate cancer patients
The European authorisation is based on the Phase III ARAMIS trial.
Ensifentrine improves lung function in COPD patients
However, the company has decided to postpone the initiation of Part B due to concerns regarding the COVID-19 pandemic.
Brilinta found to reduce bleeding vs dual therapy
Acute coronary syndrome is a type of cardiovascular disease that occurs when a blood clot forms.
COVID-19: NICE updates guideline as Sanofi announces vaccine development
Vertex has also revealed its plans to keep clinical trials going during the unstable time.
